Hans Tesch
About
Hans Tesch is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Hans Tesch has authored 346 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 199 papers in Oncology, 113 papers in Pulmonary and Respiratory Medicine and 112 papers in Cancer Research. Recurrent topics in Hans Tesch's work include Breast Cancer Treatment Studies (94 papers), Advanced Breast Cancer Therapies (73 papers) and Lymphoma Diagnosis and Treatment (69 papers). Hans Tesch is often cited by papers focused on Breast Cancer Treatment Studies (94 papers), Advanced Breast Cancer Therapies (73 papers) and Lymphoma Diagnosis and Treatment (69 papers). Hans Tesch collaborates with scholars based in Germany, United States and Switzerland. Hans Tesch's co-authors include Volker Diehl, Dieter Kube, Heribert Bohlen, Sibylle Loibl, Jens Huober, Gϋnter von Minckwitz, Michael Untch, Peter A. Fasching, Jeremy Franklin and Holger Eidtmann and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.
In The Last Decade
Hans Tesch
331 papers receiving 9.3k citations
Hit Papers
Peers
Hans Tesch
Luca Mazzucchelli Switzerland
Stephan Dirnhofer Switzerland
Jean‐François Emile France
Massimo Aglietta Italy
Gilbert Lenoir France
Thomas M. Grogan United States
George Fountzilas Greece
Bruce A. Woda United States
Ruth L. Katz United States
Yoshihiro Matsuno Japan
Citations per year, relative to Hans Tesch Hans Tesch (= 1×)
peers
Luca Mazzucchelli
Countries citing papers authored by Hans Tesch
Since
Specialization
Citations
This map shows the geographic impact of Hans Tesch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Tesch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Tesch more than expected).
Fields of papers citing papers by Hans Tesch
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Hans Tesch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Tesch. The network helps show where Hans Tesch may publish in the future.
Co-authorship network of co-authors of Hans Tesch
This figure shows the co-authorship network connecting the top 25 collaborators of Hans Tesch. A scholar is included among the top collaborators of Hans Tesch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Tesch. Hans Tesch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Loibl, S., Michael Untch, Jens Huober, et al.. (2025). 292MO Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Long-term analysis from the GeparNuevo trial. Annals of Oncology. 36. S303–S304.
2.
Costa, Luciano J., Thomas W. LeBlanc, Hans Tesch, et al.. (2024). Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future Oncology. 20(17). 1175–1189.
3.
Sinn, Bruno V., M. Untch, Thomas Karn, et al.. (2024). On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. Breast Cancer Research. 26(1). 138–138.
4.
Hannig, Carla, Kathleen Jentsch‐Ullrich, Andreas Josting, et al.. (2023). Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany. Journal of Cancer Research and Clinical Oncology. 149(10). 7197–7206.
5.
Koschmieder, Steffen, Susanne Isfort, Clemens Schulte, et al.. (2023). Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial. Annals of Hematology. 102(12). 3383–3399.
6.
Wimberger, Pauline, Jens‐Uwe Blohmer, Petra Krabisch, et al.. (2023). The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy. Breast Cancer Research. 25(1). 32–32.
7.
Schneeweiß, Andreas, Sabine Seiler, Hans Tesch, et al.. (2020). Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial. Journal of the American Heart Association. 9(23). e018143–e018143.
8.
Untch, Michael, Gϋnter von Minckwitz, Bernd Gerber, et al.. (2018). Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). Journal of Clinical Oncology. 36(13). 1308–1316.
9.
Riethdorf, Sabine, Volkmar Müller, Sibylle Loibl, et al.. (2017). Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clinical Cancer Research. 23(18). 5384–5393.
10.
Dörfel, Steffen, et al.. (2017). Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study. Breast Cancer. 25(3). 275–283.
11.
Fietz, Thomas, et al.. (2017). Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer – Results from the prospective German Tumour Registry Breast Cancer cohort study. European Journal of Cancer. 79. 139–148.
12.
Schneeweiß, Andreas, Frank Förster, Hans Tesch, et al.. (2016). First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study.. PubMed. 36(3). 967–74.
13.
Jueckstock, J, Brigitte Rack, Thomas W. P. Friedl, et al.. (2016). Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A- trial. BMC Cancer. 16(1). 401–401.
14.
Jackisch, Christian, Winfried Schoenegg, Dietmar Reichert, et al.. (2014). Trastuzumab in advanced breast cancer – a decade of experience in Germany. BMC Cancer. 14(1). 924–924.
15.
Ostermann, Helmut, Benedetto Bruno, Wolfgang Greiner, et al.. (2011). ACT-FASTER: An epidemiological prospective Cohort Study to describe treatment patterns of fulvestrant and exemestane in postmenopausal patients with advanced HR+ breast cancer under real-life conditions in Germany. PUB – Publications at Bielefeld University (Bielefeld University). 34(2). 445–50.
16.
Huober, Jens, Carsten Denkert, Hans Tesch, et al.. (2010). Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Research and Treatment. 124(1). 133–140.
17.
Riethdorf, Sabine, Volkmar Müller, Liling Zhang, et al.. (2010). Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial. Clinical Cancer Research. 16(9). 2634–2645.
18.
Minckwitz, Gϋnter von, Volker Möbus, Bettina Conrad, et al.. (2009). 0157 GAIN study: A phase III trial to compare ETC vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer. The Breast. 18. S59–S59.
19.
Diehl, Volker, et al.. (1998). Die Therapie des Morbus Hodgkin. Der Internist. 39(9). 917–926.
20.
Knethen, Andreas von, Harry F. Abts, Dieter Kube, Volker Diehl, & Hans Tesch. (1997). Expression of p56 lck in B-Cell Neoplasias. Leukemia & lymphoma. 26(5-6). 551–562.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Luca Mazzucchelli Breakdown of academic impact, for papers by Stephan Dirnhofer Breakdown of academic impact, for papers by Jean‐François Emile Breakdown of academic impact, for papers by Massimo Aglietta Breakdown of academic impact, for papers by Gilbert Lenoir Breakdown of academic impact, for papers by Thomas M. Grogan Breakdown of academic impact, for papers by George Fountzilas Breakdown of academic impact, for papers by Bruce A. Woda Breakdown of academic impact, for papers by Ruth L. Katz Breakdown of academic impact, for papers by Yoshihiro Matsuno